Evidence map›Paper›PMID 38344734›Full record

ArticleKidney international reports2024

Kidney Dysfunction and Pathology in the Setting of Hemophagocytic Lymphohistiocytosis.

Miroslav Sekulic, Ibrahim Batal, Satoru Kudose, Dominick Santoriello, M Barry Stokes, Belinda Jim, Hans-Peter Marti, Øystein Eikrem, Jai Radhakrishnan, Vivette D D'Agati and 1 more

Open access · goldAbstract read
In one paragraph

Article in Kidney international reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Miroslav SekulicDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.
Ibrahim BatalDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.
Satoru KudoseDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.
Dominick SantorielloDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.
M Barry StokesDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.
Belinda JimDepartment of Medicine, Division of Nephrology, Jacobi Medical Center at Albert Einstein College of Medicine, New York, New York, USA.
Hans-Peter MartiDepartment of Clinical Medicine, University of Bergen, Bergen, Norway.
Øystein EikremDepartment of Clinical Medicine, University of Bergen, Bergen, Norway.
Jai RadhakrishnanDepartment of Internal Medicine, Nephrology Division, Columbia University Irving Medical Center, New York, New York, USA.
Vivette D D'AgatiDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.
Glen S MarkowitzDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.
Columbia University Irving Medical Center · USHaukeland University Hospital · NOJacobi Medical Center · USUniversity of Bergen · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a clinicopathologic syndrome produced by dysregulated activation of the immune system. Acute kidney injury (AKI) and proteinuria have been infrequently described in the setting of HLH, and investigations of underlying histopathologic changes in the kidney are limited. Methods: To characterize kidney pathology in HLH, a retrospective review of 30 patients' clinical and laboratory data, and kidney tissue was performed (18 from autopsy, and 12 biopsied patients). Results: HLH was associated with infection (83%), autoimmune disease (37%), and malignancy (20%), including 30% with concurrent autoimmune disease and infection. Nephrological presentations included subnephrotic range proteinuria (63%), AKI (63%), hematuria (33%), chronic kidney disease (CKD, 20%), nephrotic range proteinuria (13%), and nephrotic syndrome (7%); and 40% of patients required hemodialysis (HD). Among the 12 patients who underwent kidney biopsy, 6 subsequently showed improved kidney function and the remainder had progressive CKD with most progressing to end-stage kidney disease. Autopsy patients had a median terminal admission of 1 month, and 33% of the biopsied patients died (ranging from 0.3-5 months post-biopsy). Variable pathologies were identified, including acute tubular injury (ATI, 43%), lupus nephritis (LN, 23%), collapsing glomerulopathy (17%), thrombotic microangiopathy (TMA, 17%), and cortical necrosis (10%). Most autopsied patients had significant kidney pathology other than ATI that likely contributed to kidney function decline. A majority of patients with HLH exhibited kidney dysfunction that likely contributed to the poor prognosis. Conclusion: Kidney dysfunction in HLH should not be assumed to be solely attributable to ATI, and in certain scenarios a kidney biopsy may be warranted.

Indexed as

autoimmune diseasehemophagocytic lymphohistiocytosishistopathologyinfectionmalignancy

Identifiers

PMID38344734
PMCPMC10851018
OpenAlexW4388460408

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.